Liwei Wang

10PUBLICATIONS
55CO-AUTHORS
Cancer diagnosisMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 24, 2026
Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025).

|Jul 09, 2026
KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial.

|Jan 06, 2025
CREB3L1 facilitates pancreatic tumor progression and reprograms intratumoral tumor-associated macrophages to shape an immunotherapy-resistance microenvironment.

Haiyan Xu, Shengbai Xue, Yang Sun

|Sep 19, 2024
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.

Jiujie Cui, Shukui Qin, Yuhong Zhou

|Jun 06, 2024
Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance.

Tommaso Scolaro, Marta Manco, Mathieu Pecqueux

|Apr 03, 2024
Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma.

Simin Wang, Yangjie Xiong, Yuxiang Luo

Pageof 2

Frequent Collaborators

2 joint publications

Xiaofei Zhang

2 joint publications

Tao Zhang

1 joint publications

Xiaolin Lin

1 joint publications

Zebing Liu